Kwok HF - Search Results

1

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.

Guo L, Wei R, Lin Y, Kwok HF. Guo L, et al. Among authors: kwok hf. Front Immunol. 2020 Jul 7;11:1508. doi: 10.3389/fimmu.2020.01508. eCollection 2020. Front Immunol. 2020. PMID: 32733486 Free PMC article. Review.

2

The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab.

Zhang SD, McCrudden CM, Meng C, Lin Y, Kwok HF. Zhang SD, et al. Among authors: kwok hf. Onco Targets Ther. 2015 Apr 15;8:835-43. doi: 10.2147/OTT.S80518. eCollection 2015. Onco Targets Ther. 2015. PMID: 25926745 Free PMC article.

3

The prognostic significance of PD-L1 in bladder cancer.

Huang Y, Zhang SD, McCrudden C, Chan KW, Lin Y, Kwok HF. Huang Y, et al. Among authors: kwok hf. Oncol Rep. 2015 Jun;33(6):3075-84. doi: 10.3892/or.2015.3933. Epub 2015 Apr 27. Oncol Rep. 2015. PMID: 25963805

4

The prognostic significance of protein tyrosine phosphatase 4A2 in breast cancer.

Zhao D, Guo L, Neves H, Yuen HF, Zhang SD, McCrudden CM, Wen Q, Zhang J, Zeng Q, Kwok HF, Lin Y. Zhao D, et al. Among authors: kwok hf. Onco Targets Ther. 2015 Jul 13;8:1707-17. doi: 10.2147/OTT.S85899. eCollection 2015. Onco Targets Ther. 2015. PMID: 26203261 Free PMC article.

5

Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.

Xiao Y, Yan W, Guo L, Meng C, Li B, Neves H, Chen PC, Li L, Huang Y, Kwok HF, Lin Y. Xiao Y, et al. Among authors: kwok hf. Mol Med Rep. 2017 Feb;15(2):941-947. doi: 10.3892/mmr.2016.6096. Epub 2016 Dec 30. Mol Med Rep. 2017. PMID: 28035421

6

The prognostic significance of DAPK1 in bladder cancer.

Xie JY, Chen PC, Zhang JL, Gao ZS, Neves H, Zhang SD, Wen Q, Chen WD, Kwok HF, Lin Y. Xie JY, et al. Among authors: kwok hf. PLoS One. 2017 Apr 7;12(4):e0175290. doi: 10.1371/journal.pone.0175290. eCollection 2017. PLoS One. 2017. PMID: 28388658 Free PMC article.

7

DAPK1 as an independent prognostic marker in liver cancer.

Li L, Guo L, Wang Q, Liu X, Zeng Y, Wen Q, Zhang S, Kwok HF, Lin Y, Liu J. Li L, et al. Among authors: kwok hf. PeerJ. 2017 Jul 19;5:e3568. doi: 10.7717/peerj.3568. eCollection 2017. PeerJ. 2017. PMID: 28740751 Free PMC article.

8

Osteopontin -- a promising biomarker for cancer therapy.

Wei R, Wong JPC, Kwok HF. Wei R, et al. Among authors: kwok hf. J Cancer. 2017 Jul 15;8(12):2173-2183. doi: 10.7150/jca.20480. eCollection 2017. J Cancer. 2017. PMID: 28819419 Free PMC article. Review.

9

Venom Peptides: Improving Specificity in Cancer Therapy.

Mahadevappa R, Ma R, Kwok HF. Mahadevappa R, et al. Among authors: kwok hf. Trends Cancer. 2017 Sep;3(9):611-614. doi: 10.1016/j.trecan.2017.07.004. Epub 2017 Aug 10. Trends Cancer. 2017. PMID: 28867164 Review.

10

β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development.

Ling YM, Chen JY, Guo L, Wang CY, Tan WT, Wen Q, Zhang SD, Deng GH, Lin Y, Kwok HF. Ling YM, et al. Among authors: kwok hf. Sci Rep. 2017 Oct 17;7(1):13404. doi: 10.1038/s41598-017-13332-0. Sci Rep. 2017. PMID: 29042578 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page